Which item is NOT typically considered a key data element for expedited reports of serious adverse reactions?

• A. Study Protocol Version
• B. Patient Details Initials
• C. Details on Reporter of Event
• D. Administrative and Sponsor/Company Details

Answer: (A)

Expedited SAE reporting centers on conveying information that identifies the patient, the event, and who is handling the report so regulators and the sponsor can act quickly. The data elements that are essential for this are those that let you link the event to a specific patient and site, know who reported it, and know how to contact the sponsor for follow-up and safety actions. The patient’s initials are included so the case can be linked to follow-up information while still protecting identity; details on the reporter identify who provided the information and allows for any needed clarifications; and administrative and sponsor/company details ensure the report reaches the right safety team and that the sponsor can coordinate required actions.

The study protocol version is not typically a key data element for the initial expedited report because it does not change the immediate clinical interpretation of the event or the urgent regulatory actions. What matters is identifying the trial (usually by protocol number) and the patient-event-reporting details needed for safety evaluation and rapid communication. Version information, while useful for document control and later audit, isn’t necessary to drive the immediate safety response.